Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

And Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Bayer BAYRY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic retinopathy who have previously responded to at least 2 intravitreal ...